Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Bought by Koshinski Asset Management Inc.

Koshinski Asset Management Inc. grew its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 6.3% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,246 shares of the medical equipment provider’s stock after acquiring an additional 253 shares during the quarter. Koshinski Asset Management Inc.’s holdings in Intuitive Surgical were worth $2,086,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of ISRG. Ridgewood Investments LLC acquired a new stake in Intuitive Surgical during the 2nd quarter worth $26,000. Creekmur Asset Management LLC boosted its stake in shares of Intuitive Surgical by 200.0% during the first quarter. Creekmur Asset Management LLC now owns 63 shares of the medical equipment provider’s stock worth $25,000 after buying an additional 42 shares during the period. LGT Financial Advisors LLC grew its holdings in shares of Intuitive Surgical by 415.4% during the second quarter. LGT Financial Advisors LLC now owns 67 shares of the medical equipment provider’s stock worth $30,000 after buying an additional 54 shares during the last quarter. Delos Wealth Advisors LLC increased its position in Intuitive Surgical by 380.0% in the 1st quarter. Delos Wealth Advisors LLC now owns 72 shares of the medical equipment provider’s stock valued at $29,000 after acquiring an additional 57 shares during the period. Finally, LRI Investments LLC purchased a new stake in Intuitive Surgical during the 1st quarter valued at approximately $30,000. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

ISRG has been the topic of a number of recent research reports. Stifel Nicolaus boosted their target price on Intuitive Surgical from $430.00 to $475.00 and gave the company a “buy” rating in a report on Friday, July 19th. Piper Sandler boosted their price objective on shares of Intuitive Surgical from $490.00 to $495.00 and gave the company an “overweight” rating in a research note on Friday, July 19th. Robert W. Baird raised their target price on shares of Intuitive Surgical from $487.00 to $503.00 and gave the stock an “outperform” rating in a research note on Friday, July 19th. BTIG Research boosted their price target on shares of Intuitive Surgical from $469.00 to $494.00 and gave the stock a “buy” rating in a research note on Wednesday, August 28th. Finally, Redburn Atlantic raised shares of Intuitive Surgical from a “neutral” rating to a “buy” rating and increased their price target for the stock from $380.00 to $510.00 in a report on Friday, August 2nd. Six investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. According to data from MarketBeat, Intuitive Surgical presently has an average rating of “Moderate Buy” and a consensus target price of $458.35.

Intuitive Surgical Trading Up 0.2 %

Shares of NASDAQ:ISRG traded up $0.94 during midday trading on Friday, hitting $484.78. 1,170,154 shares of the stock were exchanged, compared to its average volume of 1,469,034. The stock has a market cap of $172.27 billion, a P/E ratio of 83.30, a PEG ratio of 5.40 and a beta of 1.39. Intuitive Surgical, Inc. has a twelve month low of $254.85 and a twelve month high of $496.48. The company has a 50 day moving average price of $480.34 and a 200-day moving average price of $434.94.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.54 by $0.24. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. The company had revenue of $2.01 billion for the quarter, compared to the consensus estimate of $1.97 billion. During the same quarter in the prior year, the firm earned $1.18 earnings per share. The company’s revenue for the quarter was up 14.5% compared to the same quarter last year. On average, equities research analysts expect that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current year.

Insider Buying and Selling at Intuitive Surgical

In other news, Director Craig H. Barratt sold 1,400 shares of the business’s stock in a transaction on Tuesday, July 23rd. The stock was sold at an average price of $458.13, for a total value of $641,382.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Intuitive Surgical news, insider Mark Brosius sold 2,115 shares of Intuitive Surgical stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $491.91, for a total value of $1,040,389.65. Following the completion of the sale, the insider now directly owns 295 shares of the company’s stock, valued at approximately $145,113.45. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Craig H. Barratt sold 1,400 shares of the business’s stock in a transaction on Tuesday, July 23rd. The shares were sold at an average price of $458.13, for a total value of $641,382.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 53,120 shares of company stock worth $25,528,753. 0.90% of the stock is owned by insiders.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.